Operating Cash Flow
Vertex Pharmaceuticals Operating Cash Flow increased by 186.8% to $1.43B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 74.4%, from $818.90M to $1.43B. Over 3 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 11.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Consistently high operating cash flow indicates a healthy, self-sustaining business capable of funding its own growth and returning capital to shareholders.
Detailed definition
Net cash from operating activities measures the total amount of cash generated by a company's core business operations....
Peer comparison
Investors often compare this to capital expenditures to calculate Free Cash Flow, a primary valuation metric for mature tech giants.
net_cash_from_operatingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$199.77M | $927.22M | $994.99M | $956.20M | $1.14B | $955.50M | $1.08B | $899.90M | $1.13B | $1.27B | $234.60M | $1.31B | -$3.75B | $1.37B | $818.90M | $1.07B | $1.24B | $498.00M | $1.43B |
| QoQ Change | — | +564.2% | +7.3% | -3.9% | +19.2% | -16.2% | +12.9% | -16.6% | +26.1% | +11.8% | -81.5% | +456.9% | -387.3% | +136.5% | -40.2% | +31.0% | +15.7% | -59.9% | +186.8% |
| YoY Change | — | — | — | — | +670.6% | +3.1% | +8.4% | -5.9% | -0.5% | +32.7% | -78.2% | +45.2% | -430.9% | +8.0% | -37.3% | +128.6% | -9.4% | — | +74.4% |
Operating Cash Flow at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's operating cash flow?
- Vertex Pharmaceuticals (VRTX) reported operating cash flow of $1.43B in Q1 2026.
- How has Vertex Pharmaceuticals's operating cash flow changed year-over-year?
- Vertex Pharmaceuticals's operating cash flow increased by 74.4% year-over-year, from $818.90M to $1.43B.
- What is the long-term trend for Vertex Pharmaceuticals's operating cash flow?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's operating cash flow has grown at a 11.2% compound annual growth rate (CAGR), from $2.64B to $3.63B.
- What does operating cash flow mean?
- The actual amount of cash a company brings in from its day-to-day business activities.